Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorHSIEH, Ricardo-
dc.contributor.authorNICO, Marcello M. S.-
dc.contributor.authorCOUTINHO-CAMILLO, Claudia M.-
dc.contributor.authorBUIM, Marcilei E.-
dc.contributor.authorSANGUEZA, Martin-
dc.contributor.authorLOURENCO, Silvia V.-
dc.identifier.citationAMERICAN JOURNAL OF DERMATOPATHOLOGY, v.35, n.2, p.167-175, 2013-
dc.description.abstractThe etiology and pathogenesis of oral mucosal melanomas are poorly understood, and no intraoral risk factors have been identified. Recent studies have postulated that DNA repair mechanisms and cell growth pathways are involved in the development of melanoma-particularly changes in the CDKN2A (p16-cyclinD-Cdk-pRb) and MAPK pathways (RAS, BRAF, MEK 1/2, and ERK 1/2 proteins). We examined the central components of the CDKN2A and RAS-RAF-MEK-ERK cascades by immunohistochemistry in a series of 35 primary oral melanomas by tissue microarray (TMA). We noted altered expression of the CDKN2A cascade proteins, although these modulations did not correlate significantly with clinical and pathological parameters. The expression of MAP kinase cascade proteins changed in most cases. We observed that 28.57% of cases were RAS-positive and that 82.85% and 74.28% of cases were positive for BRAF and ERK2, respectively; MEK2 and ERK1 were not expressed in 48.57% and 80% of cases, and all cases were negative for MEK1. The absence of RAS and ERK1 and positivity for BRAF and ERK2 were associated with higher histological grade, vascular invasion, and metastasis. Expression of MEK2 was significantly linked to vascular invasion (P = 0.043). The CDKN2A and MAPK pathways require further study in mucosal melanomas, but our results highlight the significance of important alterations, particularly with regard to histological indicators of poor prognosis in primary oral mucosal melanomas, independent of UV exposure.-
dc.description.sponsorshipGovernmental Granting Agency-Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2010/50423-7]-
dc.relation.ispartofAmerican Journal of Dermatopathology-
dc.subjectoral mucosal melanoma-
dc.subjectCDKN2A pathway-
dc.subjectMAPK pathway-
dc.subjecttissue microarray-
dc.subject.othersporadic malignant melanomas-
dc.subject.otherprimary cutaneous melanoma-
dc.subject.othermelanocytic lesions-
dc.subject.othererk activation-
dc.subject.otherp16 expression-
dc.subject.otherbraf mutation-
dc.subject.othercyclin d1-
dc.titleThe CDKN2A and MAP Kinase Pathways: Molecular Roads to Primary Oral Mucosal Melanoma-
dc.rights.holderCopyright LIPPINCOTT WILLIAMS & WILKINS-
dc.type.categoryoriginal article-
dc.type.versionpublishedVersion-, Claudia M.:Hosp AC Camargo Fund Antonio Prudente, Dept Surg Pathol, Sao Paulo, Brazil-, Marcilei E.:Hosp AC Camargo Fund Antonio Prudente, Dept Surg Pathol, Sao Paulo, Brazil-, Martin:Hosp Obrero, Dept Pathol, La Paz, Bolivia-
hcfmusp.relation.referenceAguas SC, 2009, MED ORAL PATOL ORAL, V14, pE265-
hcfmusp.relation.referenceBartkova J, 1996, CANCER RES, V56, P5475-
hcfmusp.relation.referenceBennett DC, 2003, ONCOGENE, V22, P3063, DOI 10.1038/sj.onc.1206446-
hcfmusp.relation.referenceBuery RR, 2011, ONCOL REP, V26, P783, DOI 10.3892/or.2011.1385-
hcfmusp.relation.referenceEdlundh-Rose E, 2006, MELANOMA RES, V16, P471, DOI 10.1097/01.cmr.0000232300.22032.86-
hcfmusp.relation.referenceEmery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106-
hcfmusp.relation.referenceFemiano F, 2008, J ORAL PATHOL MED, V37, P383, DOI 10.1111/j.1600-0714.2008.00660.x-
hcfmusp.relation.referenceGhiorzo P, 2004, HUM PATHOL, V35, P25, DOI 10.1016/j.humpath.2003.08.017-
hcfmusp.relation.referenceGoel VK, 2006, J INVEST DERMATOL, V126, P154, DOI 10.1038/sj.jid.5700026-
hcfmusp.relation.referenceHicks MJ, 2000, ORAL ONCOL, V36, P152, DOI 10.1016/S1368-8375(99)00085-8-
hcfmusp.relation.referenceHilliard NJ, 2009, J CUTAN PATHOL, V36, P753, DOI 10.1111/j.1600-0560.2008.01154.x-
hcfmusp.relation.referenceHouben R, 2008, J INVEST DERMATOL, V128, P2003, DOI 10.1038/jid.2008.30-
hcfmusp.relation.referenceHsieh R, 2009, INT J DERMATOL, V48, P1303, DOI 10.1111/j.1365-4632.2008.04009.x-
hcfmusp.relation.referenceIsraels E D, 2000, Oncologist, V5, P510, DOI 10.1634/theoncologist.5-6-510-
hcfmusp.relation.referenceJarell Abel D, 2007, Biologics, V1, P407-
hcfmusp.relation.referenceJovanovic B, 2008, J INVEST DERMATOL, V128, P2696, DOI 10.1038/jid.2008.134-
hcfmusp.relation.referenceKAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634-
hcfmusp.relation.referenceKamb A, 1994, Nat Genet, V8, P23-
hcfmusp.relation.referenceKarim RZ, 2009, INT J SURG PATHOL, V17, P361, DOI 10.1177/1066896909336177-
hcfmusp.relation.referenceKong YY, 2010, ARCH PATHOL LAB MED, V134, P1740, DOI 10.1043/2009-0418-RAR.1-
hcfmusp.relation.referenceLourenco SV, 2009, AM J DERMATOPATH, V31, P323, DOI 10.1097/DAD.0b013e3181a0d37c-
hcfmusp.relation.referenceMaelandsmo GM, 1996, BRIT J CANCER, V73, P909-
hcfmusp.relation.referenceMihic-Probst D, 2006, INT J CANCER, V118, P2262, DOI 10.1002/ijc.21608-
hcfmusp.relation.referencePalmieri G, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-86-
hcfmusp.relation.referencePiccinin S, 1997, INT J CANCER, V74, P26, DOI 10.1002/(SICI)1097-0215(19970220)74:1<26::AID-IJC5>3.0.CO;2-2-
hcfmusp.relation.referenceRamirez James A, 2005, Ann Diagn Pathol, V9, P185, DOI 10.1016/j.anndiagpath.2005.04.018-
hcfmusp.relation.referenceReifenberger J, 2004, INT J CANCER, V109, P377, DOI 10.1002/ijc.11722-
hcfmusp.relation.referenceRichmond-Sinclair NM, 2008, MELANOMA RES, V18, P336, DOI 10.1097/CMR.0b013e32830d8329-
hcfmusp.relation.referenceSauter ER, 2002, CANCER RES, V62, P3200-
hcfmusp.relation.referenceScholl FA, 2009, CANCER RES, V69, P3772, DOI 10.1158/0008-5472.CAN-08-1963-
hcfmusp.relation.referenceSERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0-
hcfmusp.relation.referenceSortino-Rachou AM, 2009, ORAL ONCOL, V45, P254, DOI 10.1016/j.oraloncology.2008.04.015-
hcfmusp.relation.referenceSuzuki N, 2007, INT J ONCOL, V31, P1061-
hcfmusp.relation.referenceTanaka N, 2001, ORAL ONCOL, V37, P308, DOI 10.1016/S1368-8375(00)00107-X-
hcfmusp.relation.referenceUribe P, 2006, J INVEST DERMATOL, V126, P161, DOI 10.1038/sj.jid.5700011-
hcfmusp.relation.referenceVANTVEER LJ, 1989, MOL CELL BIOL, V9, P3114-
hcfmusp.relation.referenceVenesio T, 2008, MODERN PATHOL, V21, P716, DOI 10.1038/modpathol.2008.41-
hcfmusp.relation.referenceWang YL, 1996, BRIT J DERMATOL, V134, P269, DOI 10.1111/j.1365-2133.1996.tb07612.x-
hcfmusp.relation.referenceYeundall WA, 1995, ORAL ONCOL, V31B, P291-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MDT
Departamento de Dermatologia - FM/MDT

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - LIM/06
LIM/06 - Laboratório de Imunopatologia da Esquistossomose e outras Parasitoses

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar

Files in This Item:
File Description SizeFormat 
  Restricted Access
publishedVersion (English)1.02 MBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.